Constellium (CSTM) Earns Buy Rating from Analysts at Goldman Sachs

Goldman Sachs initiated coverage on shares of Constellium (NYSE:CSTM) in a research report released on Tuesday morning, MarketBeat.com reports. The firm issued a buy rating and a $16.00 price target on the industrial products company’s stock.

A number of other research firms have also issued reports on CSTM. Cowen set a $20.00 price objective on shares of Constellium and gave the company a buy rating in a research note on Tuesday, February 6th. Morgan Stanley set a $15.00 price objective on shares of Constellium and gave the company a buy rating in a research note on Wednesday, February 28th. ValuEngine upgraded shares of Constellium from a hold rating to a buy rating in a research note on Friday, February 2nd. Finally, Societe Generale lowered shares of Constellium from a buy rating to a hold rating in a research note on Wednesday, February 28th. Five analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $14.60.

How to Become a New Pot Stock Millionaire

Shares of Constellium (NYSE:CSTM) opened at $10.65 on Tuesday. The stock has a market cap of $1,266.98, a P/E ratio of -44.38 and a beta of 0.86. Constellium has a 12 month low of $5.35 and a 12 month high of $14.10. The company has a debt-to-equity ratio of -6.34, a quick ratio of 0.68 and a current ratio of 1.26.

Constellium (NYSE:CSTM) last posted its quarterly earnings data on Thursday, February 22nd. The industrial products company reported ($0.77) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.87). The firm had revenue of $1.25 billion for the quarter, compared to analysts’ expectations of $1.28 billion. Constellium had a negative net margin of 0.66% and a negative return on equity of 5.81%. The company’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.19) EPS. sell-side analysts forecast that Constellium will post 1.1 EPS for the current fiscal year.

Large investors have recently modified their holdings of the stock. Essex Investment Management Co. LLC bought a new stake in shares of Constellium in the fourth quarter worth $115,000. Bank of New York Mellon Corp bought a new stake in shares of Constellium in the fourth quarter worth $147,000. Jane Street Group LLC bought a new stake in shares of Constellium in the third quarter worth $187,000. Macquarie Group Ltd. bought a new stake in shares of Constellium in the third quarter worth $227,000. Finally, Capital Fund Management S.A. bought a new stake in shares of Constellium in the fourth quarter worth $442,000. Institutional investors and hedge funds own 80.66% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Constellium (CSTM) Earns Buy Rating from Analysts at Goldman Sachs” was first published by Ticker Report and is owned by of Ticker Report. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3294682/constellium-cstm-earns-buy-rating-from-analysts-at-goldman-sachs.html.

Constellium Company Profile

Constellium N.V. is a Netherlands-based company engaged in developing aluminum products for a range of markets and applications, including aerospace, automotive and packaging. The Company’s manufacturing facilities are located in the United States, Europe and China. It operates through three segments: Packaging & Automotive Rolled Product; Aerospace & Transportation, and Automotive Structures & Industry.

Analyst Recommendations for Constellium (NYSE:CSTM)

Receive News & Ratings for Constellium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellium and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

BidaskClub Downgrades Merit Medical Systems  to Hold
BidaskClub Downgrades Merit Medical Systems to Hold
Keryx Biopharmaceuticals  Upgraded at BidaskClub
Keryx Biopharmaceuticals Upgraded at BidaskClub
Alphabet  Upgraded to Buy by BidaskClub
Alphabet Upgraded to Buy by BidaskClub
Durect  Downgraded by BidaskClub
Durect Downgraded by BidaskClub
Calumet Specialty Products Partners  Stock Rating Upgraded by BidaskClub
Calumet Specialty Products Partners Stock Rating Upgraded by BidaskClub
Yext  Insider Sells $162,625.00 in Stock
Yext Insider Sells $162,625.00 in Stock


© 2006-2018 Ticker Report. Google+.